Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943904 | 0.94 | CYP3A4 (0.44) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL10871043 | 0.91 | CYP3A4 (0.46) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL8478679 | 0.88 | RAB9A (0.41) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL6959077 | 0.83 | HPGD (0.41) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL7472228 | 0.80 | CYP1A2 (0.38) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8480946 | 0.79 | RAB9A (0.41) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL7574108 | 0.78 | CYP3A4 (0.56) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL8021852 | 0.78 | CYP1A2 (0.40) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL6600354 | 0.77 | ALDH1A1 (0.45) | CYP3A4CYP2C9RAB9ACYP1A2CYP2D6 | |
| SCHEMBL11450832 | 0.76 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220392-A1 | Fatty acid synthase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1299376-A1 | FATTY ACID SYNTHASE INHIBITORS | Smithkline Beecham (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1206463-A4 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6498187-B1 | SUCH AS 2'-(6-CHLOROPIPERONYL)-3-(2,6-DICHLOROBENZYLOXY)-CINNAMIC ACID; ANTIBIOTICS | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| EP-1206464-A4 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1206464-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1206463-A1 | FATTY ACID SYNTHASE INHIBITORS | SmithKline Beecham Corporation (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001090099-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001014363-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2001014362-A1 | FATTY ACID SYNTHASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220392-A1 | Fatty acid synthase inhibitors | FASN, FADS1, FADS2 | CYP3A4 797/4885CYP2C9 802/4885RAB9A 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.